HQH
abrdn Healthcare InvestorsHQH
HQH
About: abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
0% more funds holding
Funds holding: 118 [Q3] → 118 (+0) [Q4]
1.61% less ownership
Funds ownership: 26.7% [Q3] → 25.09% (-1.61%) [Q4]
16% less capital invested
Capital invested by funds: $240M [Q3] → $200M (-$39.3M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for HQH.
Financial journalist opinion
Positive
Seeking Alpha
1 month ago
Bargain Alert: 2 Big Dividends, Up To 10% Yield
Immunize your retirement from market noise with recurring dividends. We discuss two essential sectors for reliable income generation, regardless of economic conditions. Discover our top picks with up to 10% yields.
Positive
Seeking Alpha
1 month ago
I Am Loading Up Big Dividends For My Golden Years
Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices.
Positive
Seeking Alpha
1 month ago
HQH: Improved Fundamentals, Strong Dividend Support
HQH offers a high dividend yield of 13.6%, making it attractive for income-focused investors, despite potential tax consequences. The fund trades at a 7.86% discount to NAV, presenting a good entry point, especially with anticipated interest rate cuts and increased healthcare spending. HQH's portfolio is heavily concentrated in Biotechnology (64.6%), posing sector-specific risks but also benefiting from projected growth in biotech and healthcare spending.
Neutral
Seeking Alpha
2 months ago
Aberdeen Or 'abrdn' - Either Way The Coverage Looks A Bit Thin
Closed-end funds offer unique advantages, like buying at discounts and leveraging with institutionally priced debt, making them ideal income-generating vehicles. Cash distributions are key contributors to total return, but it is essential to be sure they are actually covered by fund earnings. Some investors overly prioritize distribution yields, neglecting the importance of considering total return as a whole.
Positive
Seeking Alpha
2 months ago
Don't Miss The Dividend Train, Yields Up To 15%
For over 400 years, dividends have been a steady form of capital from the markets to your account. Dividends can generate dependable and powerful paychecks. We discuss two big yields from dependable sectors.
Negative
Seeking Alpha
3 months ago
HQH: Not For Income Investors
I maintain a sell rating on the abrdn Healthcare Investors fund due to its incongruence with income investing and managed distribution plans. HQH has underperformed the Nasdaq Biotechnology Index and iShares Biotechnology ETF, highlighting its inability to generate alpha versus more tax-efficient alternatives. The fund's high yield is unsustainable, relying on capital gains and potentially forcing premature sales, which is unsuitable for income-oriented investors.
Positive
Forbes
3 months ago
My Top Retirement Strategy For 14% Dividends In 2025
Not many people know this, but if you really want to diversify—deftly balancing and rebalancing to maximize (and protect) your gains, you need to invest in closed-end funds (CEFs).
Neutral
Seeking Alpha
3 months ago
11 Closed-End Fund Buys In The Month Of November 2024
This month, I've added to 11 different positions, but most of these were related to repurchases after the BlackRock tender offers. While I added to 11 different positions, these were all positions I had already held previously, so there were no new positions this month. In fact, I sold out of a fund to consolidate my holdings and reduce the number of funds held, as I did last month as well.
Positive
Seeking Alpha
4 months ago
2 Cyber Monday Picks I Am Buying Hand Over Fist
Buy income streams on sale, and collect your rewards for decades to come. I collect income from the market, not just cash from selling positions. Let the market fund your life; don't just dismantle your life savings.
Positive
Seeking Alpha
4 months ago
HQH: Declines Bring Potential Opportunity
HQH has seen pressure recently due to regulatory uncertainty; while the closed-end funds discount has actually narrowed, it could be an interesting place to put some capital to work. The fund's 12% managed distribution policy has attracted interest from yield investors, though a quarterly pay may be less appealing. HQH's portfolio is tilted toward a heavier weight in biotech, with top holdings like Gilead Sciences showing resilience while others like Regeneron and Eli Lilly have struggled.
Charts implemented using Lightweight Charts™